Ravulizumab

From WikiMD
Jump to navigation Jump to search
Template:Infobox drug/title
Monoclonal antibody
Type?
SourceTemplate:Infobox drug/mab source
TargetComplement component 5
Clinical data
Trade namesUltomiris
SynonymsALXN1210
[[Regulation of therapeutic goods |Template:Engvar data]]Template:Infobox drug/licence
Pregnancy
category
Template:Infobox drug/pregnancy category
Routes of
administration
intravenous infusion
ATC code
Legal status
Legal statusTemplate:Infobox drug/legal status
Pharmacokinetic data
Metabolismvarious proteases
Identifiers
CAS Number
PubChem CID
PubChem SID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
NIAID ChemDB
PDB ligand
E number{{#property:P628}}
CompTox Dashboard (EPA)
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaTemplate:Infobox drug/chemical formula
Molar massTemplate:Chem molar mass
3D model (JSmol)

Expression error: Unexpected < operator.Expression error: Unexpected < operator.Expression error: Unexpected < operator.

Ravulizumab (ALXN1210) (INN:[1] Ultomiris) is a humanized monoclonal antibody designed for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

This drug was developed by Alexion Pharmaceuticals, Inc.[2]

It was approved by the US Food and Drug Administration in December 2018.[3] In April 2019, the European CHMP of EMA recommended the granting of a conditional marketing authorisation for ravulizumab.[4]

References

  1. World Health Organization (2017). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 117" (PDF). WHO Drug Information. 31 (2).
  2. Statement On A Nonproprietary Name Adopted By The USAN Council - Ravulizumab, American Medical Association.
  3. FDA approves new treatment for adult patients with rare, life-threatening blood disease
  4. "EMA Positive Opinion - Ultomiris / ravulizumab, April 26, 2019" (PDF). ema.europa.eu. Retrieved 11 May 2019.

Template:Monoclonals for immune system

W8MD logo

Ad. Tired of being overweight?. W8MD's insurance weight loss can HELP*

Lose weight King of Prussia, PA | Lose weight NYC | Lose weight NJ | Lose weight Philadelphia | Advertise

Quick links: Medicine Portal | Encyclopedia‏‎‏‎ | Gray's Anatomy‏‎ | Topics‏‎ |‏‎ Diseases‏‎ | Drugs | Wellness | Obesity‏‎ | Metabolic syndrome | Weight loss*
Disclaimer: The entire contents of WIKIMD.ORG are for informational purposes only and do not render medical advice or professional services. If you have a medical emergency, you should CALL 911 immediately! Given the nature of the wiki, the information provided may not be accurate, misleading and or incorrect. Use the information on this wiki at your own risk! See full Disclaimer.
Link to this page: <a href="http://www.wikimd.org/wiki/Ravulizumab">Ravulizumab</a>

  • Individual results may vary for weight loss from our sponsors.

Our sponsors WikiMD is supported by W8MD weight loss, sleep and medical aesthetic centers.